Celadon Pharmaceuticals still facing cash crisis.


Celadon Pharmaceuticals reiterated on Wednesday that it has yet to receive funds under its secured credit facility, and was still facing significant funding uncertainty, raising the prospect of administration if additional financing is not secured promptly.

  • Celadon Pharmaceuticals
  • 30 April 2025 14:32:04
Celadon Pharmaceuticals

Source: Sharecast

The AIM-traded company said there had been no material progress since its 31 March update, and that it remained in discussions with the existing credit facility provider while also actively seeking alternative sources of finance.

However, Celadon cautioned that there was no guarantee of securing new funding or clarity on its timing.

Celadon previously disclosed it had limited working capital and was relying on creditor support to continue trading.

That support remained in place, and the company said it now believed it could continue operations into May.

However, it warned that without timely funding, the board may have to place the company into administration at short notice to protect stakeholder interests.

The company said it would provide further updates as appropriate.

At 1127 BST, shares in Celadon Pharmaceuticals were down 12.31% at 5.7p.

Reporting by Josh White for Sharecast.com.


Exchange: London Stock Exchange
Sell:
0.00
Buy:
0.00
Change: 9.26 ( 1.34 %)
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.